Web Desc
Tumor Immunology: Multidisciplinary Science Driving Combination Therapy
joint with Antibodies as Drugs: Immunological Scaffolds as Therapeutics
Organizer(s): Elizabeth M. Jaffee and Axel Hoos
Date: February 08 - 13, 2015
Location: Fairmont Banff Springs, Banff, AB, Canada
Sponsored by Astellas Pharma Inc., Genmab A/S, Gilead Sciences, Inc., Incyte Corporation, Infinity Pharmaceuticals, Inc., NeoStem, Inc., Regeneron Pharmaceuticals, Inc. and TESARO, Inc. Supported by an educational donation provided by Amgen.
For important information on the coronavirus, please click here
Summary of Meeting:
The field of cancer immunotherapy is evolving rapidly as a result of key scientific and developmental principles that have been discovered in recent years. New technologies together with this new knowledge have given birth to the next generation of vaccines, adoptive cellular therapies and T cell modulating agents, all of which are being investigated in preclinical models and in patients. This new era has also revealed the complex network of signaling pathways within the tumor microenvironment that currently favors the pro-carcinogenic process, but new evidence also demonstrates that this process can be altered with agents that modulate these pathways resulting in antitumor immunity. Much is being learned about the interdependency of these pathways with each other and with the non-immune cellular components within the tumor microenvironment that include the tumor, epithelial and endothelial cells, and the stroma. Thus, optimizing outcomes for patients will likely come from successfully combining immunotherapies with each other and with other classes of therapies. This will require the integration of different scientific approaches ranging from small molecule targeted therapies to complex biologics, as well as addressing molecular pathways in all of the cell subtypes within the tumor microenvironment. This conference brings together experts from academia and industry who have pioneered these areas of immunologic science, and will showcase the integration of this increasingly complicated knowledge into rapid translation into clinical applications.
Scholarship Deadline: October 9 2014
Discounted Abstract Deadline: October 9 2014
Abstract Deadline: November 12 2014
Discounted Registration Deadline: December 9 2014
Abstacts when book is in proofing process


Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
Educational donation provided by AmgenAstellas Pharma Inc.Genmab A/SGilead Sciences, Inc.Incyte CorporationInfinity Pharmaceuticals, Inc.NeoStem, Inc.Regeneron Pharmaceuticals, Inc.TESARO, Inc.
We gratefully acknowledge additional support for this conference from:
Cell Signaling Technology, Inc.eBioscience, an Affymetrix company
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

AbbVie Inc.

Amgen Inc.

BioNTech RNA Pharmaceuticals GmbH

Celgene Corporation

Genentech, Inc.

GlaxoSmithKline

Immatics Biotechnologies GmbH

Janssen R&D: Pharmaceutical Companies of Johnson & Johnson

MedImmune

Regeneron Pharmaceuticals, Inc.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
PLOS
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Sunday, February 08 | 4:00PM - 8:00PM
Arrival and Registration
Room: Van Horne Foyer


Sunday, February 08 | 6:00PM - 8:00PM
Welcome Mixer
Room: Van Horne Foyer
No registration fees are used to fund alcohol served at this function.

Monday, February 09 | 7:00AM - 8:00AM
Breakfast
Room: Mezzanine 2


Monday, February 09 | 8:00AM - 9:30AM
Keynote Session
Room: Van Horne Ballroom A/B

Speaker 1 of 2
Axel Hoos, GlaxoSmithKline, USA
Combination Therapies – Immunology Meets Oncology

Monday, February 09 | 8:00AM - 9:30AM
Keynote Session
Room: Van Horne Ballroom A/B

Speaker 2 of 2
Robert D. Schreiber, Washington University School of Medicine, USA
Using Genomics Approaches to Inform Cancer Immunotherapy

Monday, February 09 | 9:00AM - 11:30AM
Antibody Drug Conjugates in the Clinic
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 1 of 5
* Peter D. Senter, Seattle Genetics Inc., USA
Potent Antibody-Based Conjugates for Cancer Therapy: From Early-Stage Research to a Clinically Approved Drug


Monday, February 09 | 9:00AM - 11:30AM
Antibody Drug Conjugates in the Clinic
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 2 of 5
William C. Olson, Regeneron Pharmaceuticals, Inc., USA
Clinical-Stage ADCs: What's Trending Amongst this 50ish Crowd


Monday, February 09 | 9:00AM - 11:30AM
Antibody Drug Conjugates in the Clinic
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 3 of 5
Joseph J. Bellucci, Duke University, USA
Short Talk: A Non-Canonical Function of Sortase Enables Conjugation of Small Molecules to Lysine Residues in Proteins


Monday, February 09 | 9:00AM - 11:30AM
Antibody Drug Conjugates in the Clinic
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 4 of 5
Philipp Müller, University Hospital Basel, Switzerland
Short Talk: The Antibody-Drug-Conjugate T-DM1 Induces Potent Anti-Tumor Immunity in HER2+ Breast Cancer: Implications for Combinations with Immunotherapy


Monday, February 09 | 9:00AM - 11:30AM
Antibody Drug Conjugates in the Clinic
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 5 of 5
Sabine Imhof-Jung, Roche Innovation Center Penzberg, Germany
Clinical Progress with Anti-Cancer Cytolytic Fusion Proteins


Monday, February 09 | 9:30AM - 11:45AM
Inflammation and the Dynamics of the Tumor Microenvironment
Room: Van Horne Ballroom A/B

Speaker 1 of 5
Robert Peter Gale, Hammersmith and Celgene, USA
The Diversity of Myeloid Cell Populations Driving Carcinogenesis

Monday, February 09 | 9:30AM - 11:45AM
Inflammation and the Dynamics of the Tumor Microenvironment
Room: Van Horne Ballroom A/B

Speaker 2 of 5
Amy-Jo Casbon, Amgen, USA
Short Talk: Tumors Reprogram Early Myeloid Differentiation in the Bone Marrow to Generate Immunosuppressive Neutrophils

Monday, February 09 | 9:30AM - 11:45AM
Inflammation and the Dynamics of the Tumor Microenvironment
Room: Van Horne Ballroom A/B

Speaker 3 of 5
Guido Kroemer, Cordeliers Research Center, France
How Chemotherapeutics Start an Intratumoral Anticancer Immune Response

Monday, February 09 | 9:30AM - 11:45AM
Inflammation and the Dynamics of the Tumor Microenvironment
Room: Van Horne Ballroom A/B

Speaker 4 of 5
* Elizabeth M. Jaffee, Johns Hopkins University, USA
Combinatorial Immunotherapies with the Potential to Reverse the Carcinogenesis Process

Monday, February 09 | 9:30AM - 11:45AM
Inflammation and the Dynamics of the Tumor Microenvironment
Room: Van Horne Ballroom A/B

Speaker 5 of 5
Natasa Obermajer, University of Pittsburgh, USA
Short Talk: Th17 into Treg Cell Conversion: A Novel Pathway of Treg Cell Emergence

Monday, February 09 | 10:10AM - 10:30AM
Coffee Break
Room: Van Horne Foyer


Monday, February 09 | 11:45AM - 1:00PM
Poster Setup
Room: Mezzanine 2


Monday, February 09 | 11:45AM - 2:30PM
On Own for Lunch


Monday, February 09 | 1:00PM - 10:00PM
Poster Viewing
Room: Mezzanine 2


Monday, February 09 | 2:30PM - 4:30PM
Workshop 1: Integration of Science through Collaboration - N
ew Models
Room: Van Horne Ballroom A/B

Speaker 1 of 9
* Axel Hoos, GlaxoSmithKline, USA

Monday, February 09 | 2:30PM - 4:30PM
Workshop 1: Integration of Science through Collaboration - N
ew Models
Room: Van Horne Ballroom A/B

Speaker 2 of 9
* Ira Mellman, Genentech, Inc., USA

Monday, February 09 | 2:30PM - 4:30PM
Workshop 1: Integration of Science through Collaboration - N
ew Models
Room: Van Horne Ballroom A/B

Speaker 3 of 9
* Padmanee Sharma, University of Texas MD Anderson Cancer Center, USA

Monday, February 09 | 2:30PM - 4:30PM
Workshop 1: Integration of Science through Collaboration - N
ew Models
Room: Van Horne Ballroom A/B

Speaker 4 of 9
* Elizabeth M. Jaffee, Johns Hopkins University, USA

Monday, February 09 | 2:30PM - 4:30PM
Workshop 1: Integration of Science through Collaboration - N
ew Models
Room: Van Horne Ballroom A/B

Speaker 5 of 9
Arthur Machlenkin, Pantheon Biosciences Ltd, Israel
Identification of Novel Immuno-Modulatory Targets for Cancer Immunotherapy

Monday, February 09 | 2:30PM - 4:30PM
Workshop 1: Integration of Science through Collaboration - N
ew Models
Room: Van Horne Ballroom A/B

Speaker 6 of 9
Bruce Freimark, Pulse Biosciences, USA
Antibody-Mediated Blockade of Phosphatidylserine Enhances the Anti-Tumor Activity of Immune Checkpoint Inhibitors by Affecting Myeloid-Derived Suppressor Cells (MDSC) and Lymphocyte Populations in the Tumor Microenvironment

Monday, February 09 | 2:30PM - 4:30PM
Workshop 1: Integration of Science through Collaboration - N
ew Models
Room: Van Horne Ballroom A/B

Speaker 7 of 9
Marit Martha van Buuren, Neon Therapeutics, USA
Intratumoral CD4+ T Cell Reactivity Against Mutated Antigens Is Commonly Observed in Human Melanoma

Monday, February 09 | 2:30PM - 4:30PM
Workshop 1: Integration of Science through Collaboration - N
ew Models
Room: Van Horne Ballroom A/B

Speaker 8 of 9
Francisca Wollerton, F-star, UK
Modular Antibody TechnologyTM Platform Delivers Molecules of Diverse Formats and Biology

Monday, February 09 | 2:30PM - 4:30PM
Workshop 1: Integration of Science through Collaboration - N
ew Models
Room: Van Horne Ballroom A/B

Speaker 9 of 9
Jennie R. Lill, Genentech, Inc., USA
Mass-Spectrometry Based Characterization of the MHC-I Peptide Repertoire in Response to Drug Treatment

Monday, February 09 | 2:30PM - 4:30PM
Workshop 1: Novel Scaffolds
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 1 of 8
* Pablo Umaña, Roche Innovation Center Zürich, Switzerland


Monday, February 09 | 2:30PM - 4:30PM
Workshop 1: Novel Scaffolds
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 2 of 8
* Michael Stumpp, Molecular Partners, Switzerland


Monday, February 09 | 2:30PM - 4:30PM
Workshop 1: Novel Scaffolds
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 3 of 8
David P. Chimento, Rockland Immunochemicals, Inc., USA
Differential Affinity Single Domain Antibodies: Novel Agents for in vivo Imaging and Targeted Therapies


Monday, February 09 | 2:30PM - 4:30PM
Workshop 1: Novel Scaffolds
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 4 of 8
Birgit Dreier, University of Zürich, Switzerland
Generic Adenovirus Delivery System Using Bispecific DARPin-Based Adapters


Monday, February 09 | 2:30PM - 4:30PM
Workshop 1: Novel Scaffolds
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 5 of 8
Kyle Landgraf, AvidBiotics Corp., USA
Engineering Human MICA as a Novel Immunotherapeutic Scaffold


Monday, February 09 | 2:30PM - 4:30PM
Workshop 1: Novel Scaffolds
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 6 of 8
Tao Dao, Memorial Sloan Kettering, USA
Potent Therapeutic Activity of a TCR-Mimic Bi-Specific T Cell Engager Antibody against Human Cancers Expressing WT1 in the Context of HLA-A02


Monday, February 09 | 2:30PM - 4:30PM
Workshop 1: Novel Scaffolds
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 7 of 8
Johan Nilvebrant, Royal Institute of Technology, Sweden
ADAPT - A Novel Scaffold Protein for Radionuclide Molecular Imaging


Monday, February 09 | 2:30PM - 4:30PM
Workshop 1: Novel Scaffolds
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 8 of 8
Sabrina Oliveira, Utrecht University, Netherlands
Nanobody-Photosensitizer Conjugates as an Alternative Format for Targeted Photodynamic Therapy


Monday, February 09 | 4:30PM - 5:00PM
Coffee Available
Room: Van Horne Foyer


Monday, February 09 | 5:00PM - 7:15PM
Genetics and Epigenetics of the Immune System
Room: Van Horne Ballroom A/B

Speaker 1 of 5
Tak W. Mak, Campbell Family Institute for Breast Cancer, Canada
Genetic and Epigenetic Alterations that Drive Neoantigen Development

Monday, February 09 | 5:00PM - 7:15PM
Genetics and Epigenetics of the Immune System
Room: Van Horne Ballroom A/B

Speaker 2 of 5
Morten Frier Gjerstorff, University of Southern Denmark, Denmark
Short Talk: Oncogenic Functions of Cancer/Testis Antigen SSX2 Highlight its Therapeutic Potential

Monday, February 09 | 5:00PM - 7:15PM
Genetics and Epigenetics of the Immune System
Room: Van Horne Ballroom A/B

Speaker 3 of 5
* Laurence Zitvogel, Institut Gustave Roussy, France
Gut Microbiota and Anticancer Immune Responses

Monday, February 09 | 5:00PM - 7:15PM
Genetics and Epigenetics of the Immune System
Room: Van Horne Ballroom A/B

Speaker 4 of 5
Eduardo M. Sotomayor, Moffitt Cancer Center and Research Institute, USA
Combinatorial Approaches that Integrate Epigenetic Therapy with Immunotherapy

Monday, February 09 | 5:00PM - 7:15PM
Genetics and Epigenetics of the Immune System
Room: Van Horne Ballroom A/B

Speaker 5 of 5
Brian H. Ladle, Johns Hopkins University, USA
Short Talk: De novo DNA Methylation by DNMT3a Controls CD8+ T Cell Fate Decisions following Activation

Monday, February 09 | 5:00PM - 7:00PM
Antibody-Targeted Fusion Proteins for Cancer Therapy
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 1 of 4
Mark X. Sliwkowski, Genentech, Inc., USA
Antibody Therapeutics in the Treatment of HER2-Positive Cancer: Past, Present and Future


Monday, February 09 | 5:00PM - 7:00PM
Antibody-Targeted Fusion Proteins for Cancer Therapy
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 2 of 4
Sherie L. Morrison, University of California, Los Angeles, USA
Antibody Fusions with Interferon for the Treatment of Malignancy


Monday, February 09 | 5:00PM - 7:00PM
Antibody-Targeted Fusion Proteins for Cancer Therapy
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 3 of 4
* Tibor P. Keler, Celldex Therapeutics, Inc., USA
DC-Targeted Antibody Fusions as Cancer Vaccines


Monday, February 09 | 5:00PM - 7:00PM
Antibody-Targeted Fusion Proteins for Cancer Therapy
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 4 of 4
Christian Klein, Roche, Switzerland
Short Talk: CEA-Targeted IL-2 Variant (IL2v)-Based Immunocytokine for Immunotherapy of Cancer


Monday, February 09 | 7:15PM - 8:00PM
Social Hour with Lite Bites
Room: Mezzanine 2
No registration fees are used to fund alcohol served at this function.

Monday, February 09 | 7:30PM - 10:00PM
Poster Session 1
Room: Mezzanine 2


Tuesday, February 10 | 7:00AM - 8:00AM
Breakfast
Room: Mezzanine 2


Tuesday, February 10 | 8:00AM - 11:00AM
Genomic, Metabolomic and Proteomic Advances in Cancer Immuno
therapy

Room: Van Horne Ballroom A/B

Speaker 1 of 5
* Ton N. Schumacher, Netherlands Cancer Institute, Netherlands
Neo-Antigens in Human Cancer

Tuesday, February 10 | 8:00AM - 11:00AM
Genomic, Metabolomic and Proteomic Advances in Cancer Immuno
therapy

Room: Van Horne Ballroom A/B

Speaker 2 of 5
Lélia Delamarre, Genentech, Inc., USA
Short Talk: Predictive Identification of Immunogenic Mutations in Cancer

Tuesday, February 10 | 8:00AM - 11:00AM
Genomic, Metabolomic and Proteomic Advances in Cancer Immuno
therapy

Room: Van Horne Ballroom A/B

Speaker 3 of 5
Matthew M. Gubin, Washington University in St. Louis, USA
Short Talk: Checkpoint Blockade Cancer Therapy Targets Tumor-Specific Mutant Antigens

Tuesday, February 10 | 8:00AM - 11:00AM
Genomic, Metabolomic and Proteomic Advances in Cancer Immuno
therapy

Room: Van Horne Ballroom A/B

Speaker 4 of 5
Jonathan D. Powell, Johns Hopkins University School of Medicine, USA
Targeting mTOR and Metabolism to Enhance Anti-Tumor Immunotherapy

Tuesday, February 10 | 8:00AM - 11:00AM
Genomic, Metabolomic and Proteomic Advances in Cancer Immuno
therapy

Room: Van Horne Ballroom A/B

Speaker 5 of 5
Antony Rosen, Johns Hopkins University School of Medicine, USA
Cancer and the Autoimmune Rheumatic Diseases: Mechanistic Insights

Tuesday, February 10 | 8:00AM - 11:15AM
Antibodies for Cancer Immunotherapy
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 1 of 6
Alan J. Korman, Vir Biotechnology, Inc., USA
Anti-Tumor Activity of Immunomodulatory Antibodies


Tuesday, February 10 | 8:00AM - 11:15AM
Antibodies for Cancer Immunotherapy
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 2 of 6
* Martin J. Glennie, University of Southampton, UK
Agonistic Antibodies Targeting Costimulatory Receptors


Tuesday, February 10 | 8:00AM - 11:15AM
Antibodies for Cancer Immunotherapy
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 3 of 6
* Pablo Umaña, Roche Innovation Center Zürich, Switzerland
Enhancing Immune Effector Functions: Gazyva and Beyond


Tuesday, February 10 | 8:00AM - 11:15AM
Antibodies for Cancer Immunotherapy
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 4 of 6
Patrick A. Baeuerle, Amgen Research (Munich) GmbH, Germany
Clinical Progress with T Cell-Engaging Bispecific Antibodies


Tuesday, February 10 | 8:00AM - 11:15AM
Antibodies for Cancer Immunotherapy
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 5 of 6
Elizabeth E. Evans, Vaccinex, Inc., USA
Short Talk: Anti-Semaphorin 4D Therapeutic Antibody Recruits Activated Tumor Infiltrating Leukocytes and Reverses Tumor Growth


Tuesday, February 10 | 8:00AM - 11:15AM
Antibodies for Cancer Immunotherapy
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 6 of 6
Rupali Das, Children's Hospital of Philadelphia, USA
Short Talk: Cancer Immunotherapeutic Potential of NKTT320, a Novel Human iNKT Cell Activating Monoclonal Antibody


Tuesday, February 10 | 9:20AM - 9:40AM
Coffee Break
Room: Van Horne Foyer


Tuesday, February 10 | 11:00AM - 1:00PM
Poster Setup
Room: Mezzanine 2


Tuesday, February 10 | 11:00AM - 5:00PM
On Own for Lunch


Tuesday, February 10 | 1:00PM - 10:00PM
Poster Viewing
Room: Mezzanine 2


Tuesday, February 10 | 4:30PM - 5:00PM
Coffee Available
Room: Van Horne Foyer


Tuesday, February 10 | 5:00PM - 7:00PM
Human Immunology: Functional Insights for Cancer Immunothera
py

Room: Van Horne Ballroom A/B

Speaker 1 of 4
Eliane Piaggio, Immunity and Cancer - Institut Curie / INSERM, France
Short Talk: Lymph Node Invasion by Tumor Cells Modifies the Distribution and Phenotype of Dendritic and T Cell Subsets in Breast Cancer Patients

Tuesday, February 10 | 5:00PM - 7:00PM
Human Immunology: Functional Insights for Cancer Immunothera
py

Room: Van Horne Ballroom A/B

Speaker 2 of 4
* Pia Kvistborg, Netherlands Cancer Institute, Netherlands
Effects of Checkpoint Targeting on the Tumor-Specific T Cell Response

Tuesday, February 10 | 5:00PM - 7:00PM
Human Immunology: Functional Insights for Cancer Immunothera
py

Room: Van Horne Ballroom A/B

Speaker 3 of 4
Steven M. Larson, Memorial Sloan-Kettering Cancer Center, USA
Radioimmunotherapy (RIT) of Solid Tumors

Tuesday, February 10 | 5:00PM - 7:00PM
Human Immunology: Functional Insights for Cancer Immunothera
py

Room: Van Horne Ballroom A/B

Speaker 4 of 4
Jay A. Berzofsky, NCI, National Institutes of Health, USA
Talk Title to be Announced

Tuesday, February 10 | 5:00PM - 7:00PM
Alternative Tumor Targeting Approaches
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 1 of 4
* Karl Dane Wittrup, Massachusetts Institute of Technology, USA
Limits of Tumor Targeting in Immunotherapy: Theory and Experiment


Tuesday, February 10 | 5:00PM - 7:00PM
Alternative Tumor Targeting Approaches
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 2 of 4
Bryan A. Irving, CytomX Therapeutics, Inc, USA
Probodies Empower a New Generation of Antibody Immunotherapies


Tuesday, February 10 | 5:00PM - 7:00PM
Alternative Tumor Targeting Approaches
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 3 of 4
Peter Molloy, Immunocore Ltd., UK
ImmTACs: Bi-specific TCR-based Reagents for Targeted Cancer Immunotherapy


Tuesday, February 10 | 5:00PM - 7:00PM
Alternative Tumor Targeting Approaches
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 4 of 4
Heather A. Huet, Novartis Institutes for Biomedical Research, USA
Short Talk: Targeting Ovarian Cancer with ESK1, a Glycoengineered TCR-Mimic Antibody Directed Against the Intracellular Transcription Factor WT1 with Enhanced ADCC Killing


Tuesday, February 10 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Mezzanine 2
No registration fees are used to fund alcohol served at this function.

Tuesday, February 10 | 7:30PM - 10:00PM
Poster Session 2
Room: Mezzanine 2


Wednesday, February 11 | 7:00AM - 8:00AM
Breakfast
Room: Mezzanine 2


Wednesday, February 11 | 8:00AM - 11:00AM
Influence of Conventional Therapies on the Immune System
Room: Van Horne Ballroom A/B

Speaker 1 of 5
Padmanee Sharma, University of Texas MD Anderson Cancer Center, USA
From the Clinic to the Lab: Investigating Immune Responses to Immune Checkpoint Therapies


Wednesday, February 11 | 8:00AM - 11:00AM
Influence of Conventional Therapies on the Immune System
Room: Van Horne Ballroom A/B

Speaker 2 of 5
* Ira Mellman, Genentech, Inc., USA
Targeted Molecular Therapy Takes on Immunotherapy

Wednesday, February 11 | 8:00AM - 11:00AM
Influence of Conventional Therapies on the Immune System
Room: Van Horne Ballroom A/B

Speaker 3 of 5
Dan G. Duda, Harvard Medical School, Massachusetts General Hospital, USA
Short Talk: Rationally Combining Antiangiogenic Therapy with Checkpoint Inhibitors in Hepatocellular Carcinoma

Wednesday, February 11 | 8:00AM - 11:00AM
Influence of Conventional Therapies on the Immune System
Room: Van Horne Ballroom A/B

Speaker 4 of 5
Daniel E. Speiser, Ludwig Center, University of Lausanne, Switzerland
Multidisciplinary Approaches to Target both Cancer Cell-Internal and -External Disease Mechanisms

Wednesday, February 11 | 8:00AM - 11:00AM
Influence of Conventional Therapies on the Immune System
Room: Van Horne Ballroom A/B

Speaker 5 of 5
Roopa Srinivasan, GlaxoSmithKline, USA
Effects of Targeted Therapies on Tumor and Immune System

Wednesday, February 11 | 8:00AM - 11:15AM
Clinical Progress with Bispecific Antibodies for Dual Blocka
de
This session is from Antibodies as Drugs

Room: Van Horne Ballroom C

Speaker 1 of 7
* Mark X. Sliwkowski, Genentech, Inc., USA


Wednesday, February 11 | 8:00AM - 11:15AM
Clinical Progress with Bispecific Antibodies for Dual Blocka
de
This session is from Antibodies as Drugs

Room: Van Horne Ballroom C

Speaker 2 of 7
Gabriele Schaefer, Genentech, Inc., USA
MEHD7495A, a Dual-Action-Antibody Targeting HER3 and EGFR: Preclinical and Clinical Evaluation


Wednesday, February 11 | 8:00AM - 11:15AM
Clinical Progress with Bispecific Antibodies for Dual Blocka
de
This session is from Antibodies as Drugs

Room: Van Horne Ballroom C

Speaker 3 of 7
Alexey Lugovskoy, Merrimack Pharmaceuticals Inc., USA
MM-141: Dual Antibody Inhibitor of IGF-1R and ErbB3 Targeting Redundancies and Adaptation in Oncogenic Signaling


Wednesday, February 11 | 8:00AM - 11:15AM
Clinical Progress with Bispecific Antibodies for Dual Blocka
de
This session is from Antibodies as Drugs

Room: Van Horne Ballroom C

Speaker 4 of 7
Oliver Krieter, Germany
Clinical Progress with RG7221 (RO5520985), a Bi-Specific Human IgG1 Antibody Against Ang-2 and VEGF-A for the Treatment of Cancer


Wednesday, February 11 | 8:00AM - 11:15AM
Clinical Progress with Bispecific Antibodies for Dual Blocka
de
This session is from Antibodies as Drugs

Room: Van Horne Ballroom C

Speaker 5 of 7
Tariq Ghayur, AbbVie Inc., USA
Preclinical and Clinical Progress of Dual-Variable-Domain-Ig (DVD-IgTM) Molecules for Autoimmune Indications


Wednesday, February 11 | 8:00AM - 11:15AM
Clinical Progress with Bispecific Antibodies for Dual Blocka
de
This session is from Antibodies as Drugs

Room: Van Horne Ballroom C

Speaker 6 of 7
Mathias Locher, Covagen AG, Switzerland
Short Talk: COVA322: A Clinical Stage TNF/IL-17A Bispecific FynomAb for the Treatment of Inflammatory Diseases


Wednesday, February 11 | 8:00AM - 11:15AM
Clinical Progress with Bispecific Antibodies for Dual Blocka
de
This session is from Antibodies as Drugs

Room: Van Horne Ballroom C

Speaker 7 of 7
Miho Funaki, Chugai Pharmaceutical Co. Ltd., Japan
Short Talk: Novel Bispecific Antibody against Activated Factor IXa and Factor X (ACE910) for Treatment of Hemophilia A


Wednesday, February 11 | 9:20AM - 9:40AM
Coffee Break
Room: Van Horne Foyer


Wednesday, February 11 | 11:00AM - 1:00PM
Poster Setup
Room: Mezzanine 2


Wednesday, February 11 | 11:00AM - 5:00PM
On Own for Lunch


Wednesday, February 11 | 1:00PM - 10:00PM
Poster Viewing
Room: Mezzanine 2


Wednesday, February 11 | 4:30PM - 5:00PM
Coffee Available
Room: Van Horne Foyer


Wednesday, February 11 | 5:00PM - 7:15PM
Advances in Therapeutic Platforms: Vaccines, Cellular Therap
ies and Immune Modulators

Room: Van Horne Ballroom A/B

Speaker 1 of 5
Laurence J. N. Cooper, ZIOPHARM Oncology, Inc., USA
Genetic Modification of T Cells Using Sleeping Beauty System for Human Applications

Wednesday, February 11 | 5:00PM - 7:15PM
Advances in Therapeutic Platforms: Vaccines, Cellular Therap
ies and Immune Modulators

Room: Van Horne Ballroom A/B

Speaker 2 of 5
* Cornelis J. M. Melief, Leiden University Medical Center & ISA Pharmaceuticals BV, Netherlands
Synergy of Therapeutic Vaccination Against HPV16 Oncogenic Proteins and Conventional Chemotherapeutics

Wednesday, February 11 | 5:00PM - 7:15PM
Advances in Therapeutic Platforms: Vaccines, Cellular Therap
ies and Immune Modulators

Room: Van Horne Ballroom A/B

Speaker 3 of 5
Khaled H. Barakat, University of Alberta, Canada
Short Talk: Rational Design of Small Molecule Immune Checkpoints' Inhibitors

Wednesday, February 11 | 5:00PM - 7:15PM
Advances in Therapeutic Platforms: Vaccines, Cellular Therap
ies and Immune Modulators

Room: Van Horne Ballroom A/B

Speaker 4 of 5
Jolanda de Vries, NCMLS, Radboud University Medical Center, Netherlands
Natural Dendritic Cell Vaccine: A More Powerful Next Generation?

Wednesday, February 11 | 5:00PM - 7:15PM
Advances in Therapeutic Platforms: Vaccines, Cellular Therap
ies and Immune Modulators

Room: Van Horne Ballroom A/B

Speaker 5 of 5
Sandeep T. Koshy, Harvard University, USA
Short Talk: Tumor Immunomodulation Using an Injectable Biomaterials Scaffold

Wednesday, February 11 | 5:00PM - 7:00PM
Antibodies for Infectious Diseases
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 1 of 4
Gerald B. Pier, Harvard Medical School, USA
Anti-Microbial Antibody Therapy


Wednesday, February 11 | 5:00PM - 7:00PM
Antibodies for Infectious Diseases
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 2 of 4
* Antonio Lanzavecchia, Institute for Research in Biomedicine, Switzerland
Broadly Neutralizing Anti-Viral Antibodies


Wednesday, February 11 | 5:00PM - 7:00PM
Antibodies for Infectious Diseases
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 3 of 4
Yaoxing Huang, Aaron Diamond AIDS Research Center, USA
Passive Immunization Approaches to HIV Prevention


Wednesday, February 11 | 5:00PM - 7:00PM
Antibodies for Infectious Diseases
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 4 of 4
Ian Huh, California State University, Fresno, USA
Short Talk: Neutralization of Listeria monocytogenes by Single Domain Antibodies


Wednesday, February 11 | 7:15PM - 8:00PM
Social Hour with Lite Bites
Room: Mezzanine 2
No registration fees are used to fund alcohol served at this function.

Wednesday, February 11 | 7:30PM - 10:00PM
Poster Session 3
Room: Mezzanine 2


Thursday, February 12 | 7:00AM - 8:00AM
Breakfast
Room: Mezzanine 2


Thursday, February 12 | 8:00AM - 11:00AM
Methodological Advances in Clinical and Biomarker Investigat
ion

Room: Van Horne Ballroom A/B

Speaker 1 of 4
Ugur Sahin, BioNTech AG, Germany
Individualized Cancer Immunotherapy

Thursday, February 12 | 8:00AM - 11:00AM
Methodological Advances in Clinical and Biomarker Investigat
ion

Room: Van Horne Ballroom A/B

Speaker 2 of 4
James P. Allison, University of Texas MD Anderson Cancer Center, USA
Investigating Emerging Checkpoint Targets and their Modulators

Thursday, February 12 | 8:00AM - 11:00AM
Methodological Advances in Clinical and Biomarker Investigat
ion

Room: Van Horne Ballroom A/B

Speaker 3 of 4
Taha Merghoub, Memorial Sloan-Kettering Cancer Center, USA
Genetic Basis Underlying Clinical Response to Checkpoint Blockade

Thursday, February 12 | 8:00AM - 11:00AM
Methodological Advances in Clinical and Biomarker Investigat
ion

Room: Van Horne Ballroom A/B

Speaker 4 of 4
Nir Hacohen, Massachusetts General Hospital, USA
Genetic and Genomic Analysis of Tumor Immunity

Thursday, February 12 | 8:00AM - 11:15AM
Engineering Immunological Scaffolds for Improved Delivery an
d Disposition
This session is from Antibodies as Drugs

Room: Van Horne Ballroom C

Speaker 1 of 6
* Serge Muyldermans, Vrije Universiteit Brussel, Belgium
Nanobodies for Alternative Delivery Routes


Thursday, February 12 | 8:00AM - 11:15AM
Engineering Immunological Scaffolds for Improved Delivery an
d Disposition
This session is from Antibodies as Drugs

Room: Van Horne Ballroom C

Speaker 2 of 6
Kristen M. Picha, Centyrex, Janssen Research & Development, USA
Novel Delivery Strategies for Alternative Scaffolds


Thursday, February 12 | 8:00AM - 11:15AM
Engineering Immunological Scaffolds for Improved Delivery an
d Disposition
This session is from Antibodies as Drugs

Room: Van Horne Ballroom C

Speaker 3 of 6
Tomoyuki Igawa, Chugai Pharmabody Research, Singapore
Engineered pH-Dependent Binding Antibody for Efficient Elimination of Soluble Antigen from Plasma


Thursday, February 12 | 8:00AM - 11:15AM
Engineering Immunological Scaffolds for Improved Delivery an
d Disposition
This session is from Antibodies as Drugs

Room: Van Horne Ballroom C

Speaker 4 of 6
* Michael Stumpp, Molecular Partners, Switzerland
DARPins for Ocular Diseases and Beyond


Thursday, February 12 | 8:00AM - 11:15AM
Engineering Immunological Scaffolds for Improved Delivery an
d Disposition
This session is from Antibodies as Drugs

Room: Van Horne Ballroom C

Speaker 5 of 6
Yu-Ju Gloria Meng, Genentech, Inc., USA
Short Talk: Intravitreally Injected Bispecific F(ab’)2 Had Similar Intraocular Concentrations and Reduced Circulating Concentrations Compared to IgG


Thursday, February 12 | 8:00AM - 11:15AM
Engineering Immunological Scaffolds for Improved Delivery an
d Disposition
This session is from Antibodies as Drugs

Room: Van Horne Ballroom C

Speaker 6 of 6
Jens Niewoehner, Roche Pharma Research and Early Development, Germany
Short Talk: Engineering a Brain Shuttle for Therapeutic Protein Delivery


Thursday, February 12 | 9:20AM - 9:40AM
Coffee Break
Room: Van Horne Foyer


Thursday, February 12 | 11:00AM - 2:30PM
On Own for Lunch


Thursday, February 12 | 2:30PM - 4:30PM
Workshop 2: Re-Visiting Past Approaches to Cancer Immunother
apy - Lessons from Failures to Enable Future Successes
Room: Van Horne Ballroom A/B

Speaker 1 of 8
* Cornelis J. M. Melief, Leiden University Medical Center & ISA Pharmaceuticals BV, Netherlands

Thursday, February 12 | 2:30PM - 4:30PM
Workshop 2: Re-Visiting Past Approaches to Cancer Immunother
apy - Lessons from Failures to Enable Future Successes
Room: Van Horne Ballroom A/B

Speaker 2 of 8
* James P. Allison, University of Texas MD Anderson Cancer Center, USA

Thursday, February 12 | 2:30PM - 4:30PM
Workshop 2: Re-Visiting Past Approaches to Cancer Immunother
apy - Lessons from Failures to Enable Future Successes
Room: Van Horne Ballroom A/B

Speaker 3 of 8
Jason R. Baird, Earle A. Chiles Research Institute, USA
Radiation Therapy Combined with Novel Oligonucleotides Targeting STING in Tumor Stroma Result in Cure of Established Tumors

Thursday, February 12 | 2:30PM - 4:30PM
Workshop 2: Re-Visiting Past Approaches to Cancer Immunother
apy - Lessons from Failures to Enable Future Successes
Room: Van Horne Ballroom A/B

Speaker 4 of 8
Hélène Salmon, Institut Curie and Mount Sinai School of Medicine, France
In situ Activation and Expansion of CD103+ DCs at the Tumor Site Dramatically Increase Melanoma Response to BRAF and PDL1 Inhibition Therapy

Thursday, February 12 | 2:30PM - 4:30PM
Workshop 2: Re-Visiting Past Approaches to Cancer Immunother
apy - Lessons from Failures to Enable Future Successes
Room: Van Horne Ballroom A/B

Speaker 5 of 8
Katherine E. Lewis, Bristol-Myers Squibb Company, USA
Dual Targeting of PD-1 and LAG-3 Demonstrates Superior Efficacy to Blocking Either PD-1 or LAG-3 Alone in Pre-Clinical Solid and Hematological Tumor Models

Thursday, February 12 | 2:30PM - 4:30PM
Workshop 2: Re-Visiting Past Approaches to Cancer Immunother
apy - Lessons from Failures to Enable Future Successes
Room: Van Horne Ballroom A/B

Speaker 6 of 8
Carola H. Ries, Roche Innovation Center Munich, Germany
Targeting Tumor-Associated Macrophages with Anti-CSF1R Antibody in Combination with Chemotherapy

Thursday, February 12 | 2:30PM - 4:30PM
Workshop 2: Re-Visiting Past Approaches to Cancer Immunother
apy - Lessons from Failures to Enable Future Successes
Room: Van Horne Ballroom A/B

Speaker 7 of 8
Ryan Rountree, Nurix, Inc., USA
Poxvirus-Based Active Immunotherapy Induces PD-L1 Expression in the Tumor Microenvironment and Results in Dramatic Anti-Tumor Efficacy in Combination with PD-1 Axis Blockade

Thursday, February 12 | 2:30PM - 4:30PM
Workshop 2: Re-Visiting Past Approaches to Cancer Immunother
apy - Lessons from Failures to Enable Future Successes
Room: Van Horne Ballroom A/B

Speaker 8 of 8
Peter R. Rhode, Altor BioScience Corp., USA
Enhanced Efficacy of Immune Checkpoint Blockers and Therapeutic Antibodies in Combination with an IL-15-Based Superagonist Complex in Various Mouse Tumor Models

Thursday, February 12 | 2:30PM - 4:30PM
Workshop 2: New Library Design and Screening Technologies
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 1 of 8
* Pablo Umaña, Roche Innovation Center Zürich, Switzerland


Thursday, February 12 | 2:30PM - 4:30PM
Workshop 2: New Library Design and Screening Technologies
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 2 of 8
* Catherine Hutchings, Heptares Therapeutics, UK


Thursday, February 12 | 2:30PM - 4:30PM
Workshop 2: New Library Design and Screening Technologies
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 3 of 8
Belay Gessesse Bezabeh, University of Tokyo, Japan
Cell-Free Synthesis of the Human Chemokine G-Protein Coupled Receptor for Future Antibody Screening


Thursday, February 12 | 2:30PM - 4:30PM
Workshop 2: New Library Design and Screening Technologies
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 4 of 8
Ling Chen, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, China
Rapid Generation of Antiviral Antibodies for Human Application in Rhesus macaques in Responding to Emerging Influenza and Virulent Viral Infections


Thursday, February 12 | 2:30PM - 4:30PM
Workshop 2: New Library Design and Screening Technologies
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 5 of 8
Amandeep K. Gakhal, Sutro Biopharma, USA
Discovery and Characterization of Therapeutic Antibodies for an Engineered Cell-Free Expression System


Thursday, February 12 | 2:30PM - 4:30PM
Workshop 2: New Library Design and Screening Technologies
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 6 of 8
Ben Hoffstrom, Fred Hutchinson Cancer Research Center, USA
High-Throughput Screening for Monoclonal Antibodies to Multiplexed Antigens


Thursday, February 12 | 2:30PM - 4:30PM
Workshop 2: New Library Design and Screening Technologies
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 7 of 8
Michael-Paul Robinson, Cornell University, USA
Production of Full-length Antibodies in the Cytoplasm of E. coli


Thursday, February 12 | 2:30PM - 4:30PM
Workshop 2: New Library Design and Screening Technologies
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 8 of 8
Imre Kacskovics, ImmunoGenes Ltd, Hungary
Transgenic Animals that Overexpress the Neonatal Fc Receptor (FcRn) Have Improved Antibody Generation


Thursday, February 12 | 4:30PM - 5:00PM
Coffee Available
Room: Van Horne Foyer


Thursday, February 12 | 5:00PM - 6:45PM
Scientific and Clinical Progress in Combination Therapy
Room: Van Horne Ballroom A/B

Speaker 1 of 4
* Axel Hoos, GlaxoSmithKline, USA

Thursday, February 12 | 5:00PM - 6:45PM
Scientific and Clinical Progress in Combination Therapy
Room: Van Horne Ballroom A/B

Speaker 2 of 4
F. Stephen Hodi, Dana-Farber Cancer Institute, USA
Immunological Scaffolds as Therapeutics: A Phase I Trial of a Dendritic Cell Activating Scaffold Incorporating Autologous Melanoma Cell Lysate (WDVAX) in Metastatic Melanoma Patients

Thursday, February 12 | 5:00PM - 6:45PM
Scientific and Clinical Progress in Combination Therapy
Room: Van Horne Ballroom A/B

Speaker 3 of 4
Cassian Yee, University of Texas MD Anderson Cancer Center, USA
Adoptive T Cell Therapy: A Personalized Approach for Common Cancers

Thursday, February 12 | 5:00PM - 6:45PM
Scientific and Clinical Progress in Combination Therapy
Room: Van Horne Ballroom A/B

Speaker 4 of 4
Silvia C. Formenti, New York University Langone Medical Center, USA
Combination Therapy Potential of Radiation Therapy as in-situ Vaccination

Thursday, February 12 | 5:00PM - 6:45PM
Addressing Difficult Targets - GPCRs and Ion Channels
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 1 of 3
* Catherine Hutchings, Heptares Therapeutics, UK
Using Stabilized Receptors as Antigens to Generate Therapeutic Antibodies to GPCR Targets


Thursday, February 12 | 5:00PM - 6:45PM
Addressing Difficult Targets - GPCRs and Ion Channels
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 2 of 3
Vaughn V. Smider, The Scripps Research Institute, USA
Ultralong CDR3s for Targeting Ion Channels and GPCRs


Thursday, February 12 | 5:00PM - 6:45PM
Addressing Difficult Targets - GPCRs and Ion Channels
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C

Speaker 3 of 3
Caroline Colley, MedImmune, UK
Identifying Antibodies to GPCRs and Ion-Channels


Thursday, February 12 | 6:45PM - 7:15PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Room: Ballroom A/B


Thursday, February 12 | 6:45PM - 7:15PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
This session is from Antibodies as Drugs
Room: Van Horne Ballroom C


Thursday, February 12 | 7:15PM - 8:15PM
Social Hour with Lite Bites
Room: Mezzanine 2
No registration fees are used to fund alcohol served at this function.

Thursday, February 12 | 8:00PM - 11:00PM
Entertainment
Room: Mezzanine 2
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Thursday, February 12 | 8:00PM - 11:00PM
Cash Bar
Room: Mezzanine 2


Friday, February 13 | 10:23AM - 10:23AM
Departure


*Session Chair
†Invited, not yet responded.